Login to Your Account

Peripheral vision to pay off?

NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+

By Randy Osborne
Staff Writer

Monday, April 16, 2018

Kineta Inc.'s immuno-oncology (I-O) efforts have tended to grab the spotlight, but it's the push with alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists in pain that drew a deal potentially worth more than $359 million with Genentech, a unit of Roche Holding AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription